Lige Wu

4PUBLICATIONS
4CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Neurology and neuromuscular diseasesMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Mar 20, 2026
TP53 CpG Site Mutations Predict the Survival of First-Line Chemoimmunotherapy in Advanced Lung Adenocarcinoma.

Lige Wu, Zihua Zou, Yan Li

|Feb 09, 2026
Efficacy and safety of lorlatinib in first-line and subsequent-line treatments for patients with ALK-positive non-small cell lung cancer: a single-center real-world study in China.

Lige Wu, Jiayu Liu, Zihua Zou

|Jun 03, 2025
DNAJA: emerging targets for anti-tumor therapy.

Lige Wu, Puyuan Xing, Junling Li

|Jan 22, 2025
Impact of EML4-ALK Variants and TP53 Status on the Efficacy of ALK Inhibitors in Patients With Non-small Cell Lung Cancer.

Zihua Zou, Lige Wu, Xuezhi Hao

Pageof 1

Frequent Collaborators

4 joint publications

Puyuan Xing

3 joint publications

Zihua Zou

3 joint publications

Junling Li

1 joint publications

Yangchun Gu